亚宝药业签订中药新药项目技术转让协议

Core Viewpoint - The company has signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute for the new traditional Chinese medicine project, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - The company will acquire the clinical trial approval, patent rights, and related technical materials for the traditional Chinese medicine "Chaiqin Ning Shen Granules" for RMB 22 million [1] - This acquisition is categorized as a Class 1 new drug under traditional Chinese medicine [1] Group 2: Strategic Implications - The transfer of technology is expected to accelerate the company's R&D progress for new products and expand its pipeline of innovative traditional Chinese medicines [1] - The agreement aligns with the company's development strategy and is in the interest of all shareholders [1] Group 3: Impact on Financial Performance - The company indicates that due to the lengthy process of advancing various matters, there will be no significant impact on its operating performance in the short term [1]